Cost-Utility Analysis of the MiniMed ™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People with Type 1 Diabetes in France
Authors' conclusion
In people with type 1 diabetes in France not achieving glycemic target levels at baseline, the use of the MiniMed 780G system was projected to lead to substantial improvements in quality-adjusted life expectancy compared with continued use of is-CGM + MDI, with an ICUR of EUR 34,732 per QALY gained.
Study context
- Population
- People with T1D in France not achieving glycemic target levels at baseline; clinical inputs from an RCT
- Comparison
- MiniMed 780G advanced hybrid closed-loop (AHCL) system vs isCGM + MDI
- Outcome
- Incremental cost-utility ratio (ICUR)
- Follow-up
- 40-year time horizon
Methodological detailsCORE Diabetes Model (version 9.5), national payer perspective, 40-year time horizon, discounted at 2.5% per annum
- CORE Diabetes Model (version 9.5)
- National payer perspective
- 40-year time horizon
- Discounted at 2.5% per annum
Main finding
As reported in the abstract
Mean gain in quality-adjusted life expectancy
2.26 QALYs
Quality-adjusted life expectancy, direct lifetime costs and incremental cost-utility ratio (ICUR) (base case)
Mean direct lifetime costs difference
78,509 EUR
higher with MiniMed 780G
ICUR
34,732 EUR per QALY gained
Quality-adjusted life expectancy, direct lifetime costs and ICUR (base case)
Further findings
Sensitivity analyses
- Analyses were robust to changes in assumptions in most input parameters
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →